Skip to main
INSM
INSM logo

Insmed (INSM) Stock Forecast & Price Target

Insmed (INSM) Analyst Ratings

Based on 31 analyst ratings
Buy
Strong Buy 39%
Buy 55%
Hold 3%
Sell 3%
Strong Sell 0%

Bulls say

Insmed Inc. is positioned for significant growth due to the substantial diagnosed patient population for its products, particularly ARIKAYCE, which is expected to generate full-year global revenues of $405M to $425M in 2025. The anticipated launch of Brensocatib in 2025 is projected to capitalize on a $8.2B peak sales opportunity, driven by strong demand from both patients and physicians in a market lacking effective treatments. Furthermore, Insmed's expansion of its sales infrastructure and potential label expansions for Arikayce and Treprostinil Palmitil Inhalation Powder bolster the company's prospects, with the existing product portfolio already yielding consistent revenue streams.

Bears say

Insmed Inc. presents several fundamental risks that contribute to a negative outlook on its stock. The company faces uncertainties related to unexpected safety events in its drug pipeline, potential failures in securing regulatory approvals, and difficulties associated with manufacturing and commercialization, all of which could hinder revenue generation and impact financial stability. Additionally, with a reported net loss of $235.5 million for 4Q24 and $913.8 million for FY24, coupled with significant ongoing R&D expenditures, Insmed may struggle to maintain operational viability without successful product launches and positive trial outcomes.

Insmed (INSM) has been analyzed by 31 analysts, with a consensus rating of Buy. 39% of analysts recommend a Strong Buy, 55% recommend Buy, 3% suggest Holding, 3% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Insmed and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Insmed (INSM) Forecast

Analysts have given Insmed (INSM) a Buy based on their latest research and market trends.

According to 31 analysts, Insmed (INSM) has a Buy consensus rating as of Jul 10, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $72.45, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $72.45, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Insmed (INSM)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.